跳至主導覽
跳至搜尋
跳過主要內容
國立陽明交通大學研發優勢分析平台 首頁
English
中文
首頁
人員
單位
研究成果
計畫
獎項
活動
貴重儀器
影響
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
楊 慕華
教授
腫瘤惡化卓越研究中心
臨床醫學研究所
電話
(02) 2826-7000 ext. 67911/66510, +886-2-2827-7000 ext.7911
電子郵件
mhyang2
nycu.edu
tw
h-index
h10-index
h5-index
13412
引文
54
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
6514
引文
39
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
3450
引文
19
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2000
2024
每年研究成果
概覽
指紋
網路
研究成果
(256)
類似的個人檔案
(10)
指紋
查看啟用 Muh-Hwa Yang 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Keyphrases
Head-and-neck Squamous Cell Carcinoma (HNSCC)
100%
Head-and-neck Cancer
90%
Epithelial-mesenchymal Transition
74%
Oral Tongue Squamous Cell Carcinoma (OTSCC)
50%
Cancer Cells
47%
Metastasis
41%
Taiwan
39%
Chemotherapy
35%
Twist1
34%
Overexpression
32%
Recurrent Metastatic
31%
Cetuximab
31%
Overall Survival
30%
Cisplatin
30%
Tumor
27%
Prognostic Factors
27%
In Cancer
26%
Head-and-neck
26%
Colorectal Cancer
24%
Cancer Metastasis
22%
Confidence Interval
21%
Poor Prognosis
21%
National Cohort Study
21%
Tumor Microenvironment
19%
Stem Cells
19%
Cancer Patients
18%
Hypoxia
18%
Phase II Study
18%
Gastric Cancer
17%
Diffuse Large B-cell Lymphoma (DLBCL)
17%
Colorectal Cancer Stem Cells
17%
Angiogenesis
17%
BMI1
17%
Squamous Carcinoma Cells
16%
Multivariate Analysis
16%
Non-Hodgkin Lymphoma
16%
Chemoradiotherapy
16%
Squamous Cell Carcinoma of Head
15%
Treatment Outcome
15%
Phase II Trial
15%
Chronic Myeloid Leukemia
15%
Gastric Cancer Patients
15%
Perineural Invasion
15%
Paclitaxel
14%
Distant Metastasis
14%
Radiotherapy
14%
Locally Advanced
13%
Clinical Outcomes
13%
Catenin
13%
Pembrolizumab
13%
Medicine and Dentistry
Head and Neck Squamous Cell Carcinoma
55%
Head and Neck Cancer
43%
Metastatic Carcinoma
38%
Neoplasm
33%
Mouth Squamous Cell Carcinoma
31%
Overall Survival
31%
Squamous Cell Carcinoma
31%
Chemotherapy
26%
Prognostic Factor
26%
Abdominal Cancer
25%
Malignant Neoplasm
22%
Cancer Cell
22%
Neck
21%
Chemoradiotherapy
21%
Colorectal Carcinoma
20%
Disease
17%
Mesenchymal-Epithelial Transition
17%
Radiation Therapy
16%
Perineural Invasion
15%
Snail
13%
Immunity
13%
Pembrolizumab
12%
Cisplatin
12%
Chronic Myelogenous Leukemia
12%
Multivariate Analysis
12%
Angiogenesis
12%
Cohort Analysis
12%
Oral Cavity
11%
Elderly Patient
11%
Hepatocellular Carcinoma
11%
Squamous Cell Carcinoma Cell
11%
Neck Dissection
11%
Hazard Ratio
10%
Primary Tumor
10%
Distant Metastasis
10%
Nasopharynx Carcinoma
10%
Cetuximab
9%
Biological Marker
9%
Survival Rate
9%
Signal Transduction
9%
Surgery
8%
Risk Stratification
8%
Transitional Cell Carcinoma
8%
Bone Marrow Transplantation
8%
Diffuse Large B-Cell Lymphoma
8%
Placebo
8%
Upregulation
8%
Carcinogenesis
8%
Cancer Stem Cell
8%
Tumor Microenvironment
7%
